Peroxisome Proliferator-Activated Receptor Gamma Polymorphisms and Coronary Heart Disease
Table 1
Baseline characteristics of subjects with incident CHD (case) and CHD-free (control) subjects in PRIME and ADVANCE.
PRIME Men
ADVANCE Men
ADVANCE Women
Controls
Cases
P
Controls
Cases
P
Controls
Cases
P
N
494
249
433
706
372
370
Age (y)
55.1 ± 2.8
55.3 ± 3.0
.46
65.8 ± 3.3
61.5 ± 7.9
<.0001
61.5 ± 6.9
60.0 ± 8.8
.11
BMI (kg/m²)
26.7 ± 3.5
27.1 ± 3.4
.11
28.3 ± 4.4
29.1 ± 4.8
.005
27.4 ± 6.3
29.6 ± 7.2
<.0001
Waist girth (cm)
93.6 ± 10.1
95.0 ± 10.2
.067
99.4 ± 12.6
100.0 ± 12.0
.46
83.8 ± 13.6
90.4 ± 15.9
<.0001
Years at school (y)
11.26 ± 5
10.9 ± 3
.36
NA
NA
NA
NA
Physically active (%)
19.6
19.6
.99
62.6
53.8
.004
63.2
45.7
<.0001
Current smokers (%)
30.6
19.7
.0019
6.8
8.4
.36
8.4
13.0
.04
Alcohol consumption (g/week)
236 ± 310
234 ± 323
.88
50 ± 140
20 ± 70
<.0001
20 ± 70
0 ± 30
<.0001
History of hypertension (%)
17.6
30.1
.0001
51.5
78.8
<.0001
41.7
79.2
<.0001
History of dyslipidemia (%)
28.5
34.9
.06
25.4
28.6
.46
11.6
26.2
<.0001
History of diabetes (%)
4.9
8.8
.036
15.5
23.0
<.0001
5.1
21.4
<.0001
Systolic BP (mm Hg)
13 ± 19
141 ± 2
<.0001
131 ± 16
120 ± 17
<.0001
124 ± 19
121 ± 20
.08
Diastolic BP (mm Hg)
84 ± 13
87 ± 12
.0008
75 ± 8
71 ± 9
<.0001
71 ± 9
69 ± 9
.0004
Total cholesterol (mg/dL)
225 ± 37
234 ± 39
.0008
202 ± 35
NA
—
210 ± 36
NA
—
LDL-cholesterol (mg/dL)
146 ± 34
157 ± 33
.0001
124 ± 30
NA
—
124 ± 30
NA
—
HDL-cholesterol (mg/dL)
47 ± 12
43 ± 11
<.0001
49 ± 14
NA
—
62 ± 17
NA
—
Data are expressed as means ± SD or percentages. -test for continuous variables and Chi-square test for categorical variables. NA: Not available. BP: blood pressure.
